Molecular convergence of neutralizing antibodies in human revealed by repeated rabies vaccination
Rabies vaccines require repeated immunization to robustly elicit neutralizing antibodies that prevent fatal diseases. Here, we analyzed rabies glycoprotein antibody repertoires at both polyclonal and monoclonal levels following repeated vaccination. Booster vaccination dramatically elevated the neut...
Saved in:
| Published in | npj vaccines Vol. 10; no. 1; pp. 39 - 14 |
|---|---|
| Main Authors | , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
Nature Publishing Group UK
23.02.2025
Nature Publishing Group Nature Portfolio |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Rabies vaccines require repeated immunization to robustly elicit neutralizing antibodies that prevent fatal diseases. Here, we analyzed rabies glycoprotein antibody repertoires at both polyclonal and monoclonal levels following repeated vaccination. Booster vaccination dramatically elevated the neutralizing activity of recalled antibodies, primarily targeting an immunodominant site III epitope with hydrophilic and rugged structures. Strikingly, the majority of site III-directed antibodies in the recall response used a convergent V
H
gene (IGHV3-30), and they exhibited more hydrophilic and shorter paratopes than non-site III antibodies, providing physicochemical advantages for binding to site III. Additionally, several amino acids on heavy chain CDR3 were identified as key sites for acquiring an ultrapotent neutralizing activity through site III binding. Our in-depth analysis of antibody repertoires revealed the molecular signatures of neutralizing antibodies generated by repeated rabies vaccination, possibly as a result of adaptive convergence. |
|---|---|
| AbstractList | Rabies vaccines require repeated immunization to robustly elicit neutralizing antibodies that prevent fatal diseases. Here, we analyzed rabies glycoprotein antibody repertoires at both polyclonal and monoclonal levels following repeated vaccination. Booster vaccination dramatically elevated the neutralizing activity of recalled antibodies, primarily targeting an immunodominant site III epitope with hydrophilic and rugged structures. Strikingly, the majority of site III-directed antibodies in the recall response used a convergent VH gene (IGHV3-30), and they exhibited more hydrophilic and shorter paratopes than non-site III antibodies, providing physicochemical advantages for binding to site III. Additionally, several amino acids on heavy chain CDR3 were identified as key sites for acquiring an ultrapotent neutralizing activity through site III binding. Our in-depth analysis of antibody repertoires revealed the molecular signatures of neutralizing antibodies generated by repeated rabies vaccination, possibly as a result of adaptive convergence. Abstract Rabies vaccines require repeated immunization to robustly elicit neutralizing antibodies that prevent fatal diseases. Here, we analyzed rabies glycoprotein antibody repertoires at both polyclonal and monoclonal levels following repeated vaccination. Booster vaccination dramatically elevated the neutralizing activity of recalled antibodies, primarily targeting an immunodominant site III epitope with hydrophilic and rugged structures. Strikingly, the majority of site III-directed antibodies in the recall response used a convergent VH gene (IGHV3-30), and they exhibited more hydrophilic and shorter paratopes than non-site III antibodies, providing physicochemical advantages for binding to site III. Additionally, several amino acids on heavy chain CDR3 were identified as key sites for acquiring an ultrapotent neutralizing activity through site III binding. Our in-depth analysis of antibody repertoires revealed the molecular signatures of neutralizing antibodies generated by repeated rabies vaccination, possibly as a result of adaptive convergence. Rabies vaccines require repeated immunization to robustly elicit neutralizing antibodies that prevent fatal diseases. Here, we analyzed rabies glycoprotein antibody repertoires at both polyclonal and monoclonal levels following repeated vaccination. Booster vaccination dramatically elevated the neutralizing activity of recalled antibodies, primarily targeting an immunodominant site III epitope with hydrophilic and rugged structures. Strikingly, the majority of site III-directed antibodies in the recall response used a convergent VH gene (IGHV3-30), and they exhibited more hydrophilic and shorter paratopes than non-site III antibodies, providing physicochemical advantages for binding to site III. Additionally, several amino acids on heavy chain CDR3 were identified as key sites for acquiring an ultrapotent neutralizing activity through site III binding. Our in-depth analysis of antibody repertoires revealed the molecular signatures of neutralizing antibodies generated by repeated rabies vaccination, possibly as a result of adaptive convergence.Rabies vaccines require repeated immunization to robustly elicit neutralizing antibodies that prevent fatal diseases. Here, we analyzed rabies glycoprotein antibody repertoires at both polyclonal and monoclonal levels following repeated vaccination. Booster vaccination dramatically elevated the neutralizing activity of recalled antibodies, primarily targeting an immunodominant site III epitope with hydrophilic and rugged structures. Strikingly, the majority of site III-directed antibodies in the recall response used a convergent VH gene (IGHV3-30), and they exhibited more hydrophilic and shorter paratopes than non-site III antibodies, providing physicochemical advantages for binding to site III. Additionally, several amino acids on heavy chain CDR3 were identified as key sites for acquiring an ultrapotent neutralizing activity through site III binding. Our in-depth analysis of antibody repertoires revealed the molecular signatures of neutralizing antibodies generated by repeated rabies vaccination, possibly as a result of adaptive convergence. Rabies vaccines require repeated immunization to robustly elicit neutralizing antibodies that prevent fatal diseases. Here, we analyzed rabies glycoprotein antibody repertoires at both polyclonal and monoclonal levels following repeated vaccination. Booster vaccination dramatically elevated the neutralizing activity of recalled antibodies, primarily targeting an immunodominant site III epitope with hydrophilic and rugged structures. Strikingly, the majority of site III-directed antibodies in the recall response used a convergent V gene (IGHV3-30), and they exhibited more hydrophilic and shorter paratopes than non-site III antibodies, providing physicochemical advantages for binding to site III. Additionally, several amino acids on heavy chain CDR3 were identified as key sites for acquiring an ultrapotent neutralizing activity through site III binding. Our in-depth analysis of antibody repertoires revealed the molecular signatures of neutralizing antibodies generated by repeated rabies vaccination, possibly as a result of adaptive convergence. Rabies vaccines require repeated immunization to robustly elicit neutralizing antibodies that prevent fatal diseases. Here, we analyzed rabies glycoprotein antibody repertoires at both polyclonal and monoclonal levels following repeated vaccination. Booster vaccination dramatically elevated the neutralizing activity of recalled antibodies, primarily targeting an immunodominant site III epitope with hydrophilic and rugged structures. Strikingly, the majority of site III-directed antibodies in the recall response used a convergent V H gene (IGHV3-30), and they exhibited more hydrophilic and shorter paratopes than non-site III antibodies, providing physicochemical advantages for binding to site III. Additionally, several amino acids on heavy chain CDR3 were identified as key sites for acquiring an ultrapotent neutralizing activity through site III binding. Our in-depth analysis of antibody repertoires revealed the molecular signatures of neutralizing antibodies generated by repeated rabies vaccination, possibly as a result of adaptive convergence. |
| ArticleNumber | 39 |
| Author | Kewcharoenwong, Chidchamai Onodera, Taishi Ito, Naoto Suzuki, Tadaki Nithichanon, Arnone Yumoto, Kohei Lertmemongkolchai, Ganjana Fujisawa, Mizuki Sasaki, Michihito Kuroda, Daisuke Takahashi, Yoshimasa Itakura, Yukari Sawa, Hirofumi Takeoka, Shinji |
| Author_xml | – sequence: 1 givenname: Mizuki surname: Fujisawa fullname: Fujisawa, Mizuki organization: Department of Life Science and Medical Bioscience, Graduate School of Advanced Science and Engineering, Waseda University (TWIns), Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases – sequence: 2 givenname: Taishi surname: Onodera fullname: Onodera, Taishi email: taishi@niid.go.jp organization: Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases – sequence: 3 givenname: Daisuke orcidid: 0000-0003-2390-4785 surname: Kuroda fullname: Kuroda, Daisuke email: dkuroda@niid.go.jp organization: Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases – sequence: 4 givenname: Chidchamai surname: Kewcharoenwong fullname: Kewcharoenwong, Chidchamai organization: Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, The Centre for Research & Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University – sequence: 5 givenname: Michihito orcidid: 0000-0003-1607-2175 surname: Sasaki fullname: Sasaki, Michihito organization: Division of Molecular Pathobiology, International Institute for Zoonosis Control (IIZC), Hokkaido University, Institute for Vaccine Research and Development, Hokkaido University – sequence: 6 givenname: Yukari surname: Itakura fullname: Itakura, Yukari organization: Institute for Vaccine Research and Development, Hokkaido University – sequence: 7 givenname: Kohei surname: Yumoto fullname: Yumoto, Kohei organization: Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases – sequence: 8 givenname: Arnone surname: Nithichanon fullname: Nithichanon, Arnone organization: Department of Microbiology, Faculty of Medicine, Khon Kaen University – sequence: 9 givenname: Naoto surname: Ito fullname: Ito, Naoto organization: Laboratory of Zoonotic Diseases, Faculty of Applied Biological Sciences, Gifu University – sequence: 10 givenname: Shinji surname: Takeoka fullname: Takeoka, Shinji organization: Department of Life Science and Medical Bioscience, Graduate School of Advanced Science and Engineering, Waseda University (TWIns), Research Institute for Science and Engineering, Waseda University – sequence: 11 givenname: Tadaki orcidid: 0000-0002-3820-9542 surname: Suzuki fullname: Suzuki, Tadaki organization: Department of Pathology, National Institute of Infectious Diseases – sequence: 12 givenname: Hirofumi orcidid: 0000-0003-2569-2755 surname: Sawa fullname: Sawa, Hirofumi organization: Institute for Vaccine Research and Development, Hokkaido University, One Health Research Center, Hokkaido University – sequence: 13 givenname: Ganjana orcidid: 0000-0001-6972-585X surname: Lertmemongkolchai fullname: Lertmemongkolchai, Ganjana organization: Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, The Centre for Research & Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University – sequence: 14 givenname: Yoshimasa surname: Takahashi fullname: Takahashi, Yoshimasa email: ytakahas@niid.go.jp organization: Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Institute for Vaccine Research and Development, Hokkaido University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39988605$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kk9v1DAQxSNUREvpF-CAInHhEnDsOLZPCFX8qVTEBc7W2Blvvcrai52sVD49zqaUlgMnj-3fex6N3_PqJMSAVfWyJW9bwuS73LW8axtCeUNaIljDn1RnlHC1bPnJg_q0ush5SwhpRc-4IM-qU6aUlD3hZxV8jSPaeYRU2xgOmDYYLNbR1QHnKcHof_mwqSFM3sTBY659qG_mHYQ64QFhxKE2t6XeI0ylTmAW6ADW-gCTj-FF9dTBmPHibj2vfnz6-P3yS3P97fPV5YfrxnaKTo3tUTFHec-F4YahcoMwlEikEqwiopdYOOuI6yVwZwcuKHOyB-nQIRPsvLpafYcIW71PfgfpVkfw-ngQ00ZDmrwdUZuiB7TMMOU6ZzrJjRqstZyjBWNs8Xq_eu1ns8PBYlhG8cj08U3wN3oTD7ptZSfUsZs3dw4p_pwxT3rns8VxhIBxzpq1gtBeUkEK-vofdBvnFMqsCtUrqUgnaaFePWzpvpc_X1kAugI2xZwTunukJXqJjF4jo0tk9DEyehGxVZQLHDaY_r79H9Vv0VrGLA |
| Cites_doi | 10.1038/s41467-023-38063-x 10.1016/j.prevetmed.2021.105555 10.1016/j.jim.2007.09.017 10.1016/j.csbj.2023.11.056 10.1371/journal.pntd.0000542 10.1038/s41586-022-04527-1 10.1016/j.cell.2019.11.032 10.1099/jgv.0.000998 10.1038/nrmicro2260 10.1073/pnas.0904191106 10.1093/bioinformatics/btw197 10.1126/sciimmunol.abg6916 10.1002/pro.3280 10.4172/jaa.1000061 10.1146/annurev-immunol-120419-022408 10.1016/j.vaccine.2018.06.061 10.1017/S0033583500005746 10.1016/S0168-1702(97)00080-4 10.1093/cid/ciac288 10.1038/s41467-019-08489-3 10.3390/v4010117 10.1038/s41586-022-04778-y 10.7883/yoken.JJID.2018.248 10.1038/ni.3460 10.1086/515267 10.1038/s41467-020-14398-7 10.1126/sciimmunol.abq3511 10.1038/ncomms1475 10.1016/j.virusres.2016.02.002 10.1038/s41467-020-20879-6 10.1126/sciimmunol.abn8590 10.1038/s41586-020-2456-9 10.1016/j.cell.2020.09.063 10.1016/S0006-3495(02)75302-2 10.1002/jcc.21287 10.15252/emmm.201505986 10.1016/j.chom.2022.07.014 10.1016/j.imj.2022.09.003 10.1016/j.coviro.2022.101204 10.1016/S2666-5247(21)00177-4 10.4049/jimmunol.139.12.3996 10.1002/eji.200526134 10.1002/jmr.2158 10.1016/j.immuni.2017.12.009 10.1038/ni.3533 10.1016/j.immuni.2021.08.025 10.1016/S1474-4422(13)70038-3 10.1038/s41586-022-05609-w 10.1007/978-1-0716-2609-2_1 10.1073/pnas.0401786101 10.1128/jvi.62.1.1-7.1988 10.1586/14760584.2015.1011134 10.1016/S0140-6736(13)62707-5 10.1016/j.virusres.2016.10.010 10.1016/j.celrep.2021.109823 10.1007/s00430-024-00791-2 10.1016/j.chom.2019.12.012 10.1002/pro.4792 10.1038/s41590-023-01497-y 10.1016/0264-410X(92)90029-J 10.3389/fimmu.2022.910367 10.1016/j.vaccine.2021.01.023 10.1128/jvi.53.3.926-934.1985 10.1038/s41467-023-39890-8 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2025 2025. The Author(s). Copyright Nature Publishing Group 2025 The Author(s) 2025 2025 |
| Copyright_xml | – notice: The Author(s) 2025 – notice: 2025. The Author(s). – notice: Copyright Nature Publishing Group 2025 – notice: The Author(s) 2025 2025 |
| DBID | C6C AAYXX CITATION NPM 3V. 7RV 7X7 7XB 88C 8C1 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BENPR CCPQU COVID DWQXO FYUFA GHDGH K9- K9. KB0 M0R M0S M0T NAPCQ PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1038/s41541-025-01073-5 |
| DatabaseName | Springer Nature OA Free Journals CrossRef PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) Public Health ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College Coronavirus Research Database ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Consumer Health Database ProQuest Health & Medical Collection Healthcare Administration Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Publicly Available Content ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Family Health (Alumni Edition) ProQuest Central China ProQuest Central ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Public Health ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Health Management Coronavirus Research Database ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Public Health Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 2059-0105 |
| EndPage | 14 |
| ExternalDocumentID | oai_doaj_org_article_b5fcaec3b39f4fb485b9dccc55ecabbc PMC11847937 39988605 10_1038_s41541_025_01073_5 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Japan Agency for Medical Research and Development (AMED) grantid: JP243fa627009; JP23gm1810004; JP23wm0325047; JP24wm0325075; JP243fa627005; JP23wm0325047; JP22fk0108141; JP23gm1810004; JP243fa627005 funderid: https://doi.org/10.13039/100009619 – fundername: Japan Agency for Medical Research and Development (AMED) grantid: JP23wm0325047 – fundername: Japan Agency for Medical Research and Development (AMED) grantid: JP243fa627005 – fundername: Japan Agency for Medical Research and Development (AMED) grantid: JP243fa627009 – fundername: Japan Agency for Medical Research and Development (AMED) grantid: JP22fk0108141 – fundername: Japan Agency for Medical Research and Development (AMED) grantid: JP24wm0325075 – fundername: Japan Agency for Medical Research and Development (AMED) grantid: JP23gm1810004 |
| GroupedDBID | 0R~ 53G 5VS 7RV 7X7 8C1 8FI 8FJ AAJSJ ABUWG ACGFS ACSMW ADBBV AEUYN AFKRA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BCNDV BENPR C6C CCPQU EBLON EBS ECGQY FYUFA GROUPED_DOAJ HMCUK HYE K9- KQ8 M0R M0T M~E NAO NAPCQ OK1 PGMZT PIMPY RNT RPM SNYQT UKHRP AASML AAYXX CITATION PHGZM PHGZT NPM 3V. 7XB 8FK AARCD COVID DWQXO K9. PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c492t-c6e93f25657b5b3e9fd7b208e28ac90768e492cf0f68a5fcd5723f86a8fefe373 |
| IEDL.DBID | AAJSJ |
| ISSN | 2059-0105 |
| IngestDate | Wed Aug 27 01:31:27 EDT 2025 Thu Aug 21 18:27:50 EDT 2025 Thu Jul 10 22:05:13 EDT 2025 Wed Aug 13 11:32:11 EDT 2025 Thu Apr 03 07:06:14 EDT 2025 Tue Jul 01 05:40:11 EDT 2025 Mon Feb 24 01:10:12 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | 2025. The Author(s). Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c492t-c6e93f25657b5b3e9fd7b208e28ac90768e492cf0f68a5fcd5723f86a8fefe373 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0003-2569-2755 0000-0003-2390-4785 0000-0003-1607-2175 0000-0001-6972-585X 0000-0002-3820-9542 |
| OpenAccessLink | https://www.nature.com/articles/s41541-025-01073-5 |
| PMID | 39988605 |
| PQID | 3169890482 |
| PQPubID | 4669711 |
| PageCount | 14 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_b5fcaec3b39f4fb485b9dccc55ecabbc pubmedcentral_primary_oai_pubmedcentral_nih_gov_11847937 proquest_miscellaneous_3170268270 proquest_journals_3169890482 pubmed_primary_39988605 crossref_primary_10_1038_s41541_025_01073_5 springer_journals_10_1038_s41541_025_01073_5 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2025-02-23 |
| PublicationDateYYYYMMDD | 2025-02-23 |
| PublicationDate_xml | – month: 02 year: 2025 text: 2025-02-23 day: 23 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | npj vaccines |
| PublicationTitleAbbrev | npj Vaccines |
| PublicationTitleAlternate | NPJ Vaccines |
| PublicationYear | 2025 |
| Publisher | Nature Publishing Group UK Nature Publishing Group Nature Portfolio |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio |
| References | G Raghunathan (1073_CR42) 2012; 25 WW Lim (1073_CR46) 2021; 2 PD Anindita (1073_CR31) 2016; 215 M Sakharkar (1073_CR50) 2021; 6 RA Kramer (1073_CR23) 2005; 35 AR Fooks (1073_CR6) 2014; 384 P De Benedictis (1073_CR24) 2016; 8 DF Robbiani (1073_CR53) 2020; 584 World Health Organization (1073_CR2) 2018; 36 Y Aronthippaitoon (1073_CR65) 2019; 72 R Shinnakasu (1073_CR54) 2016; 17 FA Fellouse (1073_CR58) 2004; 101 Y Zurbuchen (1073_CR29) 2023; 24 AV Madsen (1073_CR40) 2024; 23 W Khamduang (1073_CR48) 2022; 199 RG Dietzgen (1073_CR11) 2017; 227 F Yang (1073_CR14) 2020; 27 C Xu (1073_CR7) 2021; 39 E Jurrus (1073_CR44) 2018; 27 C Viant (1073_CR55) 2020; 183 J Hellert (1073_CR61) 2020; 11 A Giesen (1073_CR5) 2015; 14 T Onodera (1073_CR60) 2021; 54 D Kuroda (1073_CR41) 2016; 32 M Premikha (1073_CR45) 2022; 75 1073_CR39 P Pattnaik (1073_CR4) 2023; 15 WM Ng (1073_CR59) 2022; 30 R Kotaki (1073_CR28) 2022; 7 1073_CR3 T Tiller (1073_CR63) 2008; 329 1073_CR9 1073_CR37 AAV Albertini (1073_CR13) 2012; 4 1073_CR36 D Schaefer-Babajew (1073_CR33) 2023; 613 KR McCarthy (1073_CR30) 2018; 48 N Chennamsetty (1073_CR38) 2009; 106 AH Ellebedy (1073_CR27) 2016; 17 1073_CR62 L Mesin (1073_CR56) 2020; 180 GD Victora (1073_CR49) 2022; 40 N Sinha (1073_CR35) 2002; 83 C Kewcharoenwong (1073_CR20) 2024; 213 DJ Briggs (1073_CR8) 1992; 10 F Muecksch (1073_CR32) 2022; 607 M Gidoni (1073_CR34) 2019; 10 T Hemachudha (1073_CR1) 2013; 12 I Seif (1073_CR17) 1985; 53 KA Pape (1073_CR26) 2021; 37 1073_CR21 C Prehaud (1073_CR16) 1988; 62 1073_CR68 A Strady (1073_CR10) 1998; 177 1073_CR25 H Nakamura (1073_CR43) 1996; 29 TR Luo (1073_CR64) 1997; 51 PR Blier (1073_CR57) 1987; 139 MJ Schnell (1073_CR12) 2010; 8 BR Brooks (1073_CR66) 2009; 30 M-P Lefranc (1073_CR67) 2023; 2552 NA Kuzmina (1073_CR18) 2013; 5 W Kim (1073_CR47) 2022; 604 GD de Melo (1073_CR15) 2022; 53 JS Evan (1073_CR19) 2018; 99 WD Harshbarger (1073_CR52) 2021; 12 C Shi (1073_CR22) 2022; 1 CI Kaku (1073_CR51) 2022; 7 |
| References_xml | – ident: 1073_CR39 doi: 10.1038/s41467-023-38063-x – volume: 199 year: 2022 ident: 1073_CR48 publication-title: Prev. Vet. Med. doi: 10.1016/j.prevetmed.2021.105555 – volume: 329 start-page: 112 year: 2008 ident: 1073_CR63 publication-title: J. Immunol. Methods doi: 10.1016/j.jim.2007.09.017 – volume: 23 start-page: 199 year: 2024 ident: 1073_CR40 publication-title: Comput. Struct. Biotechnol. J. doi: 10.1016/j.csbj.2023.11.056 – ident: 1073_CR25 doi: 10.1371/journal.pntd.0000542 – volume: 604 start-page: 141 year: 2022 ident: 1073_CR47 publication-title: Nature doi: 10.1038/s41586-022-04527-1 – volume: 180 start-page: 92 year: 2020 ident: 1073_CR56 publication-title: Cell doi: 10.1016/j.cell.2019.11.032 – ident: 1073_CR9 – volume: 99 start-page: 169 year: 2018 ident: 1073_CR19 publication-title: J. Gen. Virol. doi: 10.1099/jgv.0.000998 – volume: 8 start-page: 51 year: 2010 ident: 1073_CR12 publication-title: Nat. Rev. Microbiol. doi: 10.1038/nrmicro2260 – volume: 106 start-page: 11937 year: 2009 ident: 1073_CR38 publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.0904191106 – volume: 32 start-page: 2451 year: 2016 ident: 1073_CR41 publication-title: Bioinformatics doi: 10.1093/bioinformatics/btw197 – volume: 6 start-page: 1 year: 2021 ident: 1073_CR50 publication-title: Sci. Immunol. doi: 10.1126/sciimmunol.abg6916 – volume: 27 start-page: 112 year: 2018 ident: 1073_CR44 publication-title: Protein Sci. doi: 10.1002/pro.3280 – volume: 5 start-page: 037 year: 2013 ident: 1073_CR18 publication-title: J. Antivir. Antiretrovir doi: 10.4172/jaa.1000061 – volume: 40 start-page: 413 year: 2022 ident: 1073_CR49 publication-title: Annu Rev. Immunol. doi: 10.1146/annurev-immunol-120419-022408 – volume: 36 start-page: 5500 year: 2018 ident: 1073_CR2 publication-title: Vaccine doi: 10.1016/j.vaccine.2018.06.061 – volume: 29 start-page: 1 year: 1996 ident: 1073_CR43 publication-title: Q. Rev. Biophys. doi: 10.1017/S0033583500005746 – volume: 51 start-page: 35 year: 1997 ident: 1073_CR64 publication-title: Virus Res. doi: 10.1016/S0168-1702(97)00080-4 – volume: 75 start-page: 1442 year: 2022 ident: 1073_CR45 publication-title: Clin. Infect. Dis. doi: 10.1093/cid/ciac288 – volume: 10 year: 2019 ident: 1073_CR34 publication-title: Nat. Commun. doi: 10.1038/s41467-019-08489-3 – ident: 1073_CR21 – volume: 4 start-page: 117 year: 2012 ident: 1073_CR13 publication-title: Viruses doi: 10.3390/v4010117 – volume: 607 start-page: 128 year: 2022 ident: 1073_CR32 publication-title: Nature doi: 10.1038/s41586-022-04778-y – volume: 15 start-page: e50424 year: 2023 ident: 1073_CR4 publication-title: Cureus – volume: 72 start-page: 99 year: 2019 ident: 1073_CR65 publication-title: Jpn J. Infect. Dis. doi: 10.7883/yoken.JJID.2018.248 – volume: 17 start-page: 861 year: 2016 ident: 1073_CR54 publication-title: Nat. Immunol. doi: 10.1038/ni.3460 – volume: 177 start-page: 1290 year: 1998 ident: 1073_CR10 publication-title: J. Infect. Dis. doi: 10.1086/515267 – volume: 11 start-page: 25 year: 2020 ident: 1073_CR61 publication-title: Nat. Commun. doi: 10.1038/s41467-020-14398-7 – volume: 7 year: 2022 ident: 1073_CR51 publication-title: Sci. Immunol. doi: 10.1126/sciimmunol.abq3511 – ident: 1073_CR62 doi: 10.1038/ncomms1475 – volume: 215 start-page: 121 year: 2016 ident: 1073_CR31 publication-title: Virus Res. doi: 10.1016/j.virusres.2016.02.002 – volume: 12 start-page: 1 year: 2021 ident: 1073_CR52 publication-title: Nat. Commun. doi: 10.1038/s41467-020-20879-6 – volume: 7 start-page: 1 year: 2022 ident: 1073_CR28 publication-title: Sci. Immunol. doi: 10.1126/sciimmunol.abn8590 – volume: 584 start-page: 437 year: 2020 ident: 1073_CR53 publication-title: Nature doi: 10.1038/s41586-020-2456-9 – volume: 183 start-page: 1298 year: 2020 ident: 1073_CR55 publication-title: Cell doi: 10.1016/j.cell.2020.09.063 – volume: 83 start-page: 2946 year: 2002 ident: 1073_CR35 publication-title: Biophys. J. doi: 10.1016/S0006-3495(02)75302-2 – volume: 30 start-page: 1545 year: 2009 ident: 1073_CR66 publication-title: J. Comput. Chem. doi: 10.1002/jcc.21287 – volume: 8 start-page: 407 year: 2016 ident: 1073_CR24 publication-title: EMBO Mol. Med. doi: 10.15252/emmm.201505986 – volume: 30 start-page: 1219 year: 2022 ident: 1073_CR59 publication-title: Cell Host Microbe doi: 10.1016/j.chom.2022.07.014 – volume: 1 start-page: 262 year: 2022 ident: 1073_CR22 publication-title: Infect. Med. doi: 10.1016/j.imj.2022.09.003 – volume: 53 start-page: 101204 year: 2022 ident: 1073_CR15 publication-title: Curr. Opin. Virol. doi: 10.1016/j.coviro.2022.101204 – volume: 2 start-page: e423 year: 2021 ident: 1073_CR46 publication-title: Lancet Microbe doi: 10.1016/S2666-5247(21)00177-4 – volume: 139 start-page: 3996 year: 1987 ident: 1073_CR57 publication-title: J. Immunol. doi: 10.4049/jimmunol.139.12.3996 – ident: 1073_CR3 – volume: 35 start-page: 2131 year: 2005 ident: 1073_CR23 publication-title: Eur. J. Immunol. doi: 10.1002/eji.200526134 – volume: 25 start-page: 103 year: 2012 ident: 1073_CR42 publication-title: J. Mol. Recognit. doi: 10.1002/jmr.2158 – volume: 48 start-page: 174 year: 2018 ident: 1073_CR30 publication-title: Immunity doi: 10.1016/j.immuni.2017.12.009 – volume: 17 start-page: 1226 year: 2016 ident: 1073_CR27 publication-title: Nat. Immunol. doi: 10.1038/ni.3533 – volume: 54 start-page: 2385 year: 2021 ident: 1073_CR60 publication-title: Immunity doi: 10.1016/j.immuni.2021.08.025 – volume: 12 start-page: 498 year: 2013 ident: 1073_CR1 publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(13)70038-3 – volume: 613 start-page: 735 year: 2023 ident: 1073_CR33 publication-title: Nature doi: 10.1038/s41586-022-05609-w – volume: 2552 start-page: 3 year: 2023 ident: 1073_CR67 publication-title: Methods Mol. Biol. doi: 10.1007/978-1-0716-2609-2_1 – volume: 101 start-page: 12467 year: 2004 ident: 1073_CR58 publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.0401786101 – volume: 62 start-page: 1 year: 1988 ident: 1073_CR16 publication-title: J. Virol. doi: 10.1128/jvi.62.1.1-7.1988 – volume: 14 start-page: 351 year: 2015 ident: 1073_CR5 publication-title: Expert Rev. Vaccines doi: 10.1586/14760584.2015.1011134 – volume: 384 start-page: 1389 year: 2014 ident: 1073_CR6 publication-title: Lancet doi: 10.1016/S0140-6736(13)62707-5 – volume: 227 start-page: 158 year: 2017 ident: 1073_CR11 publication-title: Virus Res. doi: 10.1016/j.virusres.2016.10.010 – volume: 37 year: 2021 ident: 1073_CR26 publication-title: Cell Rep. doi: 10.1016/j.celrep.2021.109823 – volume: 213 start-page: 7 year: 2024 ident: 1073_CR20 publication-title: Med. Microbiol. Immunol. doi: 10.1007/s00430-024-00791-2 – volume: 27 start-page: 441 year: 2020 ident: 1073_CR14 publication-title: Cell Host Microbe doi: 10.1016/j.chom.2019.12.012 – ident: 1073_CR68 doi: 10.1002/pro.4792 – volume: 24 start-page: 955 year: 2023 ident: 1073_CR29 publication-title: Nat. Immunol. doi: 10.1038/s41590-023-01497-y – volume: 10 start-page: 125 year: 1992 ident: 1073_CR8 publication-title: Vaccine doi: 10.1016/0264-410X(92)90029-J – ident: 1073_CR36 doi: 10.3389/fimmu.2022.910367 – volume: 39 start-page: 1044 year: 2021 ident: 1073_CR7 publication-title: Vaccine doi: 10.1016/j.vaccine.2021.01.023 – volume: 53 start-page: 926 year: 1985 ident: 1073_CR17 publication-title: J. Virol. doi: 10.1128/jvi.53.3.926-934.1985 – ident: 1073_CR37 doi: 10.1038/s41467-023-39890-8 |
| SSID | ssj0001763570 |
| Score | 2.2916975 |
| Snippet | Rabies vaccines require repeated immunization to robustly elicit neutralizing antibodies that prevent fatal diseases. Here, we analyzed rabies glycoprotein... Abstract Rabies vaccines require repeated immunization to robustly elicit neutralizing antibodies that prevent fatal diseases. Here, we analyzed rabies... |
| SourceID | doaj pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 39 |
| SubjectTerms | 631/250/2152/2153/1291 631/250/590/1883 Antigens Bats Biomedical and Life Sciences Biomedicine Immunization Infectious Diseases Medical Microbiology Monoclonal antibodies Proteins Public Health R&D Rabies Research & development RNA polymerase Science Vaccine Vaccines Virology Zoonoses |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEB6hnrggKK9Ai4yEemGjpna8to-AqCqkoh5aqTfL49hiL9mqu0Vafj0zTna3y0NcuEWxo1gzY8_T3wC8S46sjECnH5Jw1O0JmjoE19UyWRltTjYjB_TPv07Prtov1_r6Xqsvrgkb4IEHwh2jzjGkqFC53GZsrUbXxRi1TjEgRj59Sefdc6ZKdKXgrDXjLZlG2eMFaaqWPGfJtWok17Xe0UQFsP9PVubvxZK_ZEyLIjp9DI9GC1J8GFb-BB6kfh-OLgYI6tVEXG5vVC0m4khcbMGpV08hnK_74YpScF7uXiYxz6KnTzjq8YP-KojeM5xzhaGY9aI08hMM9kTqpBO4oucbOsTp-TYgT_oeYpwNgcVncHX6-fLTWT22Wahj6-SyjtPkVJac_0SNKrncGZSNTdKG6DhTl2hezE2e2kDc6LSRKttpIFbmpIx6Dnv9vE8vQbD3lp0JxjbYttmGJitGTCMbsUum6Sp4vya5vxnQNHzJgivrBwZ5YpAvDPK6go_Mlc1MRsIuL0g-_Cgf_l_yUcHBmqd-3J4Lr064byYdXrKCt5th2licLQl9mt_xHEP-qZWmqeDFIAKblZBVZy05ghXYHeHYWeruSD_7VsC7yaHjYKapYLKWo-26_k6LV_-DFq_hoSwbQNZSHcDe8vYuHZJNtcQ3Zfv8BPm0JBA priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB5BuXBBtLxCCzIS6oWNmtrx2jkhQFQVUlEPrbQ3y3Zs2Euy7G6Rtr--M06y0fLoLUocxfF8tuflbwDehwq1DIurn0Nw5OWpU7m1VZ3zoLnXMejoyKF_8X16fl1-m8lZ73Bb9WmVw5qYFuq69eQjPxGnVOoQ8cY_Ln7lVDWKoqt9CY2H8IioywjVaqZGH0tiWyv6szKF0Ccr3K9KtJ85ZawhunO5sx8l2v5_6Zp_p0z-ETdN29HZU3jS65HsUyf4fXgQmgM4vuyIqDcTdjWeq1pN2DG7HCmqN8_AXgxVcVlKO08nMANrI2vwFfJ93OJXGY763LWUZ8jmDUvl_BhRPuGmUjO3wesFLuV4vbSOGv223s879-JzuD77evXlPO-LLeS-rPg699NQicgpCuqkE6GKtXK80IFr6yuK1wVs52MRp9rK6GupuIh6alGgMQglXsBe0zbhFTCy4WKlrNKFK8uobREF8aahplgHVdQZfBiG3Cw6Tg2TYuFCm05ABgVkkoCMzOAzSWXbkviw0412-cP008s47JENXjhRxTK6UktX1d57KYO3zvkMjgaZmn6SrswIqQzebR_j9KKYiW1Ce0NtFFqpmqsig5cdBLY9Qd1OazQHM9A74Njp6u6TZv4zUXijWUcuTZXBZMDR2K__j8Xr-3_jEB7zBG2ec3EEe-vlTXiDOtPavU0T4w6QWBgy priority: 102 providerName: ProQuest |
| Title | Molecular convergence of neutralizing antibodies in human revealed by repeated rabies vaccination |
| URI | https://link.springer.com/article/10.1038/s41541-025-01073-5 https://www.ncbi.nlm.nih.gov/pubmed/39988605 https://www.proquest.com/docview/3169890482 https://www.proquest.com/docview/3170268270 https://pubmed.ncbi.nlm.nih.gov/PMC11847937 https://doaj.org/article/b5fcaec3b39f4fb485b9dccc55ecabbc |
| Volume | 10 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3Na9swFH_04zIYZe0-6q0NGoxeFjNHsi35mIaWktGSbS3kJiRZ2nKxS5IO0r--T7KdkK077GIb-9k8_J6k9_kTwCdboJWhcPbTqBxxOtA8VqooY2oFNcJZ4bQP6F_f5Fd36XiaTXeAdr0woWg_QFqGabqrDvuywIUmRceX-lIzVMs424V9D9WOur0_HI5_jDeRlYCxlrQdMgkTz7y8tQoFsP7nLMy_CyX_yJaGRejyFRy01iMZNvwewo6tjuBs0sBPr_rkdtNNteiTMzLZAFOvjuBlE6MjTevRa1DX3d64JBSfhz5MS2pHKvyEj4A8IhcE__1M177akMwqEjb1Ix74CZeWkugVXt_jhI7Xc6U90W9lzKwJMr6Bu8uL29FV3G65EJu0oMvY5LZgjvpcqM40s4UruaaJsFQoU_isnUU64xKXC5U5U2acMidyhWJ1lnH2FvaqurLHQLwn5wquuEh0mjqhEsc8ehrai6XlSRnB504E8r5B1pAhI86EbAQmUWAyCExmEZx7Ka0pPSp2uFHPf8pWS6RGjpQ1TLPCpU6nItNFaYzJMmuU1iaCk07Gsh2qC8kGfg9NnMhoBB_Xj3GQ-cyJqmz94Gk4-qqC8iSCd41KrDlBC08IdAojEFvKssXq9pNq9isAeaNz5wObPIJ-p1cbvv79L97_H_kHeEGD6tOYshPYW84f7ClaUkvdg10-5XgUo0GvHUZ4Pr-4mXzHu6N81AsxCjx-_SaeAF9BIjM |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3LbtNAcFTKAS6Idw0FFgl6IVadXTteHxCCQpXSpuohlXpbdte7kIsdkhQUPopvZGZtJwqvW2-WvbbHnpmd9wzAC1eglqFx9zNIHHHaN3msdVHG3ElupXfSG3Loj04Hw_P040V2sQU_u1oYSqvs9sSwUZe1JR_5vujTqEOkN_5m-jWmqVEUXe1GaDRkceyW39Fkm78-eo_4fcn54YfxwTBupwrENi34IrYDVwjPKdxnMiNc4cvc8EQ6LrUtKDDlcJ31iR9InXlbZjkXXg40Qu6dyAU-9xpcTwWyJlWmH_TXPp3Q3S1pa3MSIffnKB9TtNc5ZcghN8XZhvwLYwL-ptv-maL5W5w2iL_D23Cr1VvZ24bQ7sCWq-7C3lnT-HrZY-N1Hde8x_bY2bol9vIe6FE3hZeFNPdQ8elY7VmFt5Cv5Qe-lSGWJ6amvEY2qVgYH8ioxRQKsZKZJR5PUXTg8UwbWvRNWztp3Jn34fxK0PAAtqu6cjvAyGb0Ra5zmZg09VInXlCfNtRMS5cnZQSvul-upk0PDxVi70KqBkEKEaQCglQWwTvCymol9d8OJ-rZZ9WyszIIkXZWGFH41JtUZqYorbVZ5qw2xkaw2-FUtZvCXK1JOILnq8vIzhSj0ZWrL2lNjlax5HkSwcOGBFaQoC4pJZqfEcgN4tgAdfNKNfkSWoajGUku1DyCXkdHa7j-_S8e_f8znsGN4Xh0ok6OTo8fw00eyJzHXOzC9mJ26Z6gvrYwTwOTMPh01Vz5C38TVcc |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR1db9Mw8DQ6CSEhBOMrMMBIsBcaSO2kdh54KIxq69hUiU3am2c7NvQlqdoOVH4Qv5Ozk7QqjAce9mYlJ-vkO_u-7wBe2Ry1DIWvn0bmiNOe5rFSeRFTK6gRzgqnvUP_-KR_cJaOzrPzLfjV1sKEpP3Q0jI802122Ls5CpoUDV_qU82QLePs7bRwTTLlkV3-QFNt_v5wH-n6mtLhp9OPB3EzTSA2aU4XsenbnDnqw3w608zmruCaJsJSoUzuA1IW4YxLXF-ozJki45Q50VeIsbOMM9z3Bmyjft9LO7A9GIy-jNbenNDXLWmqchImrkB4Q_KFAQFXabV_J2f-EaENgm94F-40GisZ1Gd0D7ZsuQN747rl9bJLTtcVXPMu2SPjdTPs5Q7crv2CpC53ug_quJ3HS0LCe6j9tKRypMQtvNflJ2JBkN4TXfkMRzIpSRgkSHyzKRRnBdFLXE9RiOB6prQH-q6MmdSOzQdwdi2EeQidsirtYyDeenQ5V1wkOk2dUIljvmMb6qiF5UkRwZuWBHJad_OQIQrPhKwJJpFgMhBMZhF88FRaQfpO3OFDNfsqG86UGjFS1jDNcpc6nYpM54UxJsusUVqbCHZbGsvmeZhL1vNzO_HxpBG8XP3Gi-2jNaq01aWH4WgfC8qTCB7VLLHCBLVKIdAQjUBsMMsGqpt_ysm30DwcDUrvTOURdFu-WuP177N48n_gL-DmeH8oPx-eHD2FWzTcAhpTtgudxezSPkNFbqGfN7eIwMV1X9zf58xbEA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Molecular+convergence+of+neutralizing+antibodies+in+human+revealed+by+repeated+rabies+vaccination&rft.jtitle=npj+vaccines&rft.au=Fujisawa%2C+Mizuki&rft.au=Onodera%2C+Taishi&rft.au=Kuroda%2C+Daisuke&rft.au=Kewcharoenwong%2C+Chidchamai&rft.date=2025-02-23&rft.pub=Nature+Publishing+Group+UK&rft.eissn=2059-0105&rft.volume=10&rft.issue=1&rft_id=info:doi/10.1038%2Fs41541-025-01073-5&rft.externalDocID=10_1038_s41541_025_01073_5 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2059-0105&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2059-0105&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2059-0105&client=summon |